300 related articles for article (PubMed ID: 25253666)
21. Cytokine mRNA expression and proliferative responses induced by pertussis toxin, filamentous hemagglutinin, and pertactin of Bordetella pertussis in the peripheral blood mononuclear cells of infected and immunized schoolchildren and adults.
He Q; Tran Minh NN; Edelman K; Viljanen MK; Arvilommi H; Mertsola J
Infect Immun; 1998 Aug; 66(8):3796-801. PubMed ID: 9673264
[TBL] [Abstract][Full Text] [Related]
22. An evaluation of the safety and immunogenicity of a five-component acellular pertussis, diphtheria, and tetanus toxoid vaccine (DTaP) when combined with a Haemophilus influenzae type b-tetanus toxoid conjugate vaccine (PRP-T) in Taiwanese infants.
Lee CY; Thipphawong J; Huang LM; Lee PI; Chiu HH; Lin W; Debois H; Harrison D; Xie F; Barreto L
Pediatrics; 1999 Jan; 103(1):25-30. PubMed ID: 9917435
[TBL] [Abstract][Full Text] [Related]
23. Immunological persistence in 5 y olds previously vaccinated with hexavalent DTPa-HBV-IPV/Hib at 3, 5, and 11 months of age.
Silfverdal SA; Assudani D; Kuriyakose S; Van Der Meeren O
Hum Vaccin Immunother; 2014; 10(10):2795-8. PubMed ID: 25483640
[TBL] [Abstract][Full Text] [Related]
24. Cell-mediated immunity after pertussis vaccination and after natural infection.
Zepp F; Knuf M; Habermehl P; Schmitt HJ; Meyer C; Clemens R; Slaoui M
Dev Biol Stand; 1997; 89():307-14. PubMed ID: 9272364
[TBL] [Abstract][Full Text] [Related]
25. Safety and immunogenicity of a combined Tetanus, Diphtheria, recombinant acellular Pertussis vaccine (TdaP) in healthy Thai adults.
Sirivichayakul C; Chanthavanich P; Limkittikul K; Siegrist CA; Wijagkanalan W; Chinwangso P; Petre J; Hong Thai P; Chauhan M; Viviani S
Hum Vaccin Immunother; 2017 Jan; 13(1):136-143. PubMed ID: 27686283
[TBL] [Abstract][Full Text] [Related]
26. Functional deficits of pertussis-specific CD4+ T cells in infants compared to adults following DTaP vaccination.
Sharma SK; Pichichero ME
Clin Exp Immunol; 2012 Sep; 169(3):281-91. PubMed ID: 22861368
[TBL] [Abstract][Full Text] [Related]
27. Impact of infant and preschool pertussis vaccinations on memory B-cell responses in children at 4 years of age.
Hendrikx LH; de Rond LG; Oztürk K; Veenhoven RH; Sanders EA; Berbers GA; Buisman AM
Vaccine; 2011 Aug; 29(34):5725-30. PubMed ID: 21669247
[TBL] [Abstract][Full Text] [Related]
28. Maternal pertussis vaccination and its effects on the immune response of infants aged up to 12 months in the Netherlands: an open-label, parallel, randomised controlled trial.
Barug D; Pronk I; van Houten MA; Versteegh FGA; Knol MJ; van de Kassteele J; Berbers GAM; Sanders EAM; Rots NY
Lancet Infect Dis; 2019 Apr; 19(4):392-401. PubMed ID: 30938299
[TBL] [Abstract][Full Text] [Related]
29. Immunogenicity and Safety of Monovalent Acellular Pertussis Vaccine at Birth: A Randomized Clinical Trial.
Wood N; Nolan T; Marshall H; Richmond P; Gibbs E; Perrett K; McIntyre P
JAMA Pediatr; 2018 Nov; 172(11):1045-1052. PubMed ID: 30208475
[TBL] [Abstract][Full Text] [Related]
30. Pertussis specific cell-mediated immune responses ten years after acellular pertussis booster vaccination in young adults.
Gröndahl-Yli-Hannuksela K; Kauko L; Van Der Meeren O; Mertsola J; He Q
Vaccine; 2016 Jan; 34(3):341-9. PubMed ID: 26643932
[TBL] [Abstract][Full Text] [Related]
31. Anti-pertussis antibody kinetics following DTaP-IPV booster vaccination in Norwegian children 7-8 years of age.
Aase A; Herstad TK; Jørgensen SB; Leegaard TM; Berbers G; Steinbakk M; Aaberge I
Vaccine; 2014 Oct; 32(45):5931-6. PubMed ID: 25218299
[TBL] [Abstract][Full Text] [Related]
32. Antibody and cell-mediated immune responses to booster immunization with a new acellular pertussis vaccine in school children.
Tran Minh NN; Edelman K; He Q; Viljanen MK; Arvilommi H; Mertsola J
Vaccine; 1998 Oct; 16(17):1604-10. PubMed ID: 9713935
[TBL] [Abstract][Full Text] [Related]
33. Cell-mediated and antibody responses to Bordetella pertussis antigens in children vaccinated with acellular or whole-cell pertussis vaccines. The Progetto Pertosse-CMI Working Group.
Cassone A; Ausiello CM; Urbani F; Lande R; Giuliano M; La Sala A; Piscitelli A; Salmaso S
Arch Pediatr Adolesc Med; 1997 Mar; 151(3):283-9. PubMed ID: 9080938
[TBL] [Abstract][Full Text] [Related]
34. A phase I, randomized, controlled, dose-ranging study of investigational acellular pertussis (aP) and reduced tetanus-diphtheria-acellular pertussis (TdaP) booster vaccines in adults.
Leroux-Roels G; Lattanzi M; Solis CD; Contorni M; Costantini M; Moraschini L; Bardelli M; Bertholet S; Borgogni E; Buricchi F; Cantisani R; Faenzi E; Finco O; Leuzzi R; Pizza M; Rosa D; Schiavetti F; Seubert A; Spensieri F; Volpini G; Zedda L; Giudice GD; Galgani I
Hum Vaccin Immunother; 2018 Jan; 14(1):45-58. PubMed ID: 29172945
[TBL] [Abstract][Full Text] [Related]
35. Robust Humoral and Cellular Immune Responses to Pertussis in Adults After a First Acellular Booster Vaccination.
van der Lee S; van Rooijen DM; de Zeeuw-Brouwer ML; Bogaard MJM; van Gageldonk PGM; Marinovic AB; Sanders EAM; Berbers GAM; Buisman AM
Front Immunol; 2018; 9():681. PubMed ID: 29670634
[TBL] [Abstract][Full Text] [Related]
36. Reduced-antigen, combined diphtheria, tetanus and acellular pertussis vaccine, adsorbed (Boostrix®): a review of its properties and use as a single-dose booster immunization.
McCormack PL
Drugs; 2012 Sep; 72(13):1765-91. PubMed ID: 22931522
[TBL] [Abstract][Full Text] [Related]
37. Antibody response and reactions to completion of a four-dose series with a two- or three-component acellular pertussis vaccine compared to whole cell pertussis vaccine.
Pichichero ME; Green JL; Francis AB; Marsocci SM; Murphy AM; Buscarino C
Scand J Infect Dis; 1996; 28(2):159-63. PubMed ID: 8792483
[TBL] [Abstract][Full Text] [Related]
38. Reduced-antigen, combined diphtheria-tetanus-acellular pertussis vaccine, adsorbed (Boostrix) US formulation): use as a single-dose booster immunization in adolescents aged 10-18 years.
Frampton JE; Keam SJ
Paediatr Drugs; 2006; 8(3):189-95; discussion 196. PubMed ID: 16774298
[TBL] [Abstract][Full Text] [Related]
39. Immunization of teenagers with a fifth dose of reduced DTaP-IPV induces high levels of pertussis antibodies with a significant increase in opsonophagocytic activity.
Aase A; Herstad TK; Merino S; Bolstad M; Sandbu S; Bakke H; Aaberge IS
Clin Vaccine Immunol; 2011 Aug; 18(8):1269-74. PubMed ID: 21677109
[TBL] [Abstract][Full Text] [Related]
40. The Effect of Maternal Pertussis Immunization on Infant Vaccine Responses to a Booster Pertussis-Containing Vaccine in Vietnam.
Maertens K; Hoang TT; Nguyen TD; Caboré RN; Duong TH; Huygen K; Hens N; Van Damme P; Dang DA; Leuridan E
Clin Infect Dis; 2016 Dec; 63(suppl 4):S197-S204. PubMed ID: 27838673
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
